Codex DNA Gross Profit

As of the most recent data (September 2024), DNAY shows a gross profit of $8.9M. That compares with $16M in the prior-year period — down 45.5% year over year. That is below the Healthcare sector average of $67B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, DNAY's gross profit is now $8.9M (was $16M) — a 45.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Codex DNA is outperforming or lagging.

The Healthcare sector average gross profit is about $67B. Codex DNA is at $8.9M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how DNAY stacks up against individual peers as well.

Tracking DNAY's gross profit over time shows whether Codex DNA is scaling, shrinking, or reshaping that part of the business. The current reading is $8.9M That compares with $16M in the prior-year period — down 45.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this gross profit page, Stockcircle has Codex DNA's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect gross profit (currently $8.9M) with ownership activity and broader fundamentals.